Dr Palmer
Al-Ali HK et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol 2020;189(5):888-903. Abstract
Al-Ali HK et al. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma 2016;57(10):2464-7. Abstract
Cervantes F et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: The REALISE phase 2 study. Leukemia 2021;35(12):3455-65. Abstract
Gerds A et al. Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: A case series. Clin Lymphoma Myeloma Leuk 2018;18(11):e463-8. Abstract
Gupta V et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica 2016;101(12):e482-4. Abstract
Harrison CN et al. Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 trials. EHA 2021;Abstract S203.
Harrison CN et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 2020;95(6):594-603. Abstract
Harrison CN et al. Case series of potential Wernicke's encephalopathy in patients treated with fedratinib. ASH 2017;Abstract 4197.
Harrison CN et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4(7):e317-24. Abstract
Harrison CN et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016;30(8):1701-7. Abstract
Harrison CN et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98. Abstract
Kuykendall AT et al. Between a rux and a hard place: Evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol;97(3):435-41. Abstract
Maffioli M et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 2022;6(6):1855-64. Abstract
Newberry KJ et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 2017;130(9):1125-1131. Abstract
Palandri F et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 2020;126(6):1243-52. Abstract
Pardanani A et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1(5):643-51. Abstract
Scott BL et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2017;35(11):1154-61. Abstract
Verstovsek S et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood 2012;120(6):1202-9. Abstract
Verstovsek S et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807. Abstract
Zhang Q et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernicke's encephalopathy. Drug Metab Dispos 2014;42(10):1656-62. Abstract
Dr Oh
Gerds AT et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): An updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol 2023;10(9):e735-46. Abstract
Gupta V et al. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma 2024;65(7):965-77. Abstract
Naymagon L, Mascarenhas L. Myelofibrosis-related anemia: Current and emerging therapeutic strategies. Hemasphere 2017;1(1). Abstract
Nicolosi M et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: Analysis based on 1109 consecutive patients. Leukemia 2018;32(5):1254-8. Abstract
Oh ST et al. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem 2024;5(1):105-16. Abstract
Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;7(19):5835-42. Abstract
Oh ST et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv 2020;4(18):4282-91. Abstract
Tefferi A et al. One thousand patients with primary myelofibrosis: The Mayo Clinic experience. Mayo Clin Proc 2012;87(1):25-33. Abstract
Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401(10373):269-80. Abstract
Verstovsek S et al. MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 2021;17(12):1449-58. Abstract
Verstovsek S et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate/high risk myelofibrosis patients. ASH 2020;Abstract 54.
Dr Rampal
Ajufo H et al. Pacritinib response is associated with overall survival in myelofibrosis: PERSIST-2 landmark analysis of survival. Eur J Haematol 2025;114(2):238-47. Abstract
Alhuraiji A et al. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. ASCO 2016;Abstract 7068.
Gerds AT et al. Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv 2020;4(22):5825-35. Abstract
Hernandez-Boluda JC et al. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. Br J Haematol 2018;181(3):397-400. Abstract
Marcellino BK et al. The myelodepletive phenotype in myelofibrosis: Clinical relevance and therapeutic implication. Clin Lymphoma Myeloma Leuk 2020;20(7):415-21. Abstract
Masarova L et al. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. Leuk Res 2020;91:106338. Abstract
Masarova L et al. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 2018;100(3):257-63. Abstract
Mascarenhas J et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-9. Abstract
Scotch AH et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res 2017;63:34-40. Abstract
Vachhani P et al. Platelet response in pacritinib-treated patients with cytopenic myelofibrosis: A retrospective analysis of PERSIST-2 and PAC203 studies. ASH 2023;Abstract 4554.
Prof Harrison
Bose P et al. Odyssey: A phase 2 open-label study of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis. ASH 2024;Abstract 3191.2.
Fenaux P et al. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood 2019;133(8):790-4. Abstract
Gerds AT et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv 2024;8(17):4511-22. Abstract
Mascarenhas J et al. INCA33989 is a novel, first in class, mutant calreticulin-specific monoclonal antibody that demonstrates safety and efficacy in patients with essential thrombocythemia (ET). EHA 2025;Abstract LBA4002.
Mascarenhas J et al. Results from the randomized, multicenter, global phase 3 BOREAS study: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.
Mead A et al. Interim analysis of Promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib. ASH 2024;Abstract 3186.
Vachhani P et al. Disease-modifying activity of navtemadlin (NVTM) correlated with survival outcomes in Janus kinase inhibitor (JAKI) relapsed or refractory (R/R) myelofibrosis (MF) patients (PTS). EHA 2023;Abstract S214.
Vannucchi AM et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 study. EHA 2025;Abstract S223.
Dr Kuykendall
Bose P et al. Initial results from Summit: An ongoing, 3-part, multi-center, randomized, double-blind, placebo-controlled phase 2 clinical study of bezuclastinib in adult patients with nonadvanced systemic mastocytosis (NonAdvSM). ASH 2023;Abstract 77.
Castells M et al. Efficacy and safety of avapritinib in indolent systemic mastocytosis (ISM): Results from the double-blind placebo-controlled PIONEER study. AAAAI 2023;Abstract 627.
Chifotides HT, Bose P. SOHO state of the art update and next questions: Current and emerging therapies for systemic mastocytosis. Clin Lymphoma Myeloma Leuk 2025;25(1):1-12. Abstract
DeAngelo DJ et al. An updated analysis on safety and efficacy of avapritinib in patients with advanced systemic mastocytosis from the Explorer clinical study: Long-term efficacy and safety. ASH 2022;Abstract.
Gotlib J et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 PATHFINDER trial. Nat Med 2021;27(12):2192-9. Abstract
Mesa RA et al. Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM patient survey. Cancer 2022 Oct;128(20):3691-9. Abstract
Mukherjee S et al. Decreased survival among patients with indolent systemic mastocytosis: A population-level retrospective cohort analysis using healthcare claims dataset. ASH 2023;Abstract 75.
Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 2019;94(3):363-77. Abstract
Radia DH et. al. Avapritinib as first-line therapy in patients with advanced systemic mastocytosis: Efficacy and safety from the PATHFINDER clinical study. ASH 2022;Abstract.
Tashi T et al. Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: Analysis of the HARBOR trial. ASH 2023;Abstract 76.
Valent P et al. Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM/ECNM. J Allergy Clin Immunol Pract 2024;12(12):3250-60.e5. Abstract